When Should You SELL Your Stocks (8 Reasons to Sell Your Stocks) Click to watch on Youtube.

$19.50 (-7.41%)

Volume: 5.374M

Closed: Aug 10, 2022

Hollow Logo Score: -2.619

Exelixis Stock Forecast

BUY NASDAQ:EXEL
$19.50 (-7.41%)

Volume: 5.374M

Closed: Aug 10, 2022

Score Hollow Logo -2.619

Exelixis Stock News NASDAQ:EXEL

Why Is Exelixis (EXEL) Down 3.1% Since Last Earnings Report?

03:30pm, Thursday, 09'th Jun 2022 Zacks Investment Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Read more

4 Supercharged Growth Stocks Billionaires Can't Stop Buying

09:21am, Wednesday, 08'th Jun 2022 The Motley Fool
Successful money managers piled into these fast-growing companies in the first quarter. Read more

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

01:45pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. Read more

Exelixis (EXEL) Announces Results From Phase II HNSCC Study

02:10pm, Friday, 27'th May 2022 Zacks Investment Research
Exelixis (EXEL) phase II study evaluating Cabometyx in combination with Keytruda in patients with recurrent or metastatic head and neck squamous cell carcinoma meets primary goal. Read more

3 Stocks That Could Make You a Fortune Over the Next 10 Years

11:05am, Saturday, 21'st May 2022 The Motley Fool
They have one key common denominator. Read more

Can This Cancer Stock Maintain Its Momentum?

02:23pm, Wednesday, 18'th May 2022 The Motley Fool
This biotech stock has been on fire since the beginning of the year. Read more

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

10:20am, Wednesday, 18'th May 2022 Zacks Investment Research
Smart Beta ETF report for XBI Read more
With thrilling long-term prospects, these three are excellent buys. Read more

Exelixis (EXEL) Q1 2022 Earnings Call Transcript

07:00pm, Wednesday, 11'th May 2022 The Motley Fool
EXEL earnings call for the period ending March 31, 2022. Read more

Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates

06:08pm, Wednesday, 11'th May 2022 Zacks Investment Research
Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure. Read more

Exelixis (EXEL) Tops Q1 Earnings Estimates

09:25pm, Tuesday, 10'th May 2022 Zacks Investment Research
Exelixis (EXEL) delivered earnings and revenue surprises of 50% and 6.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock? Read more
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer Acquires Biohaven For $11B Pfizer Inc (NYSE: PFE) will acquire Biohaven Pharmaceutical Hold Read more

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

10:20am, Tuesday, 10'th May 2022 Zacks Investment Research
Sector ETF report for FBT Read more

Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More

03:37pm, Monday, 09'th May 2022 Zacks Investment Research
Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10. Read more

Why Exelixis (EXEL) Might Surprise This Earnings Season

12:48pm, Monday, 09'th May 2022 Zacks Investment Research
Exelixis (EXEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. Read more

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE